
FDA delays approval decision for Biohaven rare disease drug
Connecticut-based Biohaven has been developing what it hopes will be the first medicine for a group of rare, nerve-destroying diseases. The company ran a couple late-stage clinical trials, submitted an approval application to the Food and Drug …